Home » Stocks » SVA

Sinovac Biotech Ltd. (SVA)

NASDAQ halted the trading of Sinovac stock in February, 2019.
Stock Price: $6.47 USD 0.00 (0.00%)
Updated Nov 3, 2021 5:00 PM EDT
Market Cap 460.25M
Revenue (ttm) 246.05M
Net Income (ttm) 39.80M
Shares Out 94.88M
EPS (ttm) 0.28
PE Ratio 22.94
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Nov 3, 2021
Last Price $6.47
Previous Close $6.47
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 6.47 - 6.47
Day's Volume 0
52-Week Range 6.47 - 6.47

News

Hide News
Business Wire - 5 months ago

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the Fourth Intermediat...

Business Wire - 5 months ago

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the inactivated COVID-...

Business Wire - 5 months ago

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently comme...

Benzinga - 5 months ago

Sinovac Biotech has plans to expand the clinical trial of its COVID-19 vaccine trial to children and adolescents later this month.

Business Wire - 5 months ago

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced that the inactivated COVID-19 va...

Business Wire - 6 months ago

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial re...

Business Wire - 6 months ago

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has signed two agreemen...

The Motley Fool - 7 months ago

Leaders and laggards in the COVID-19 vaccine race -- and how likely they are to win approval.

Other stocks mentioned: AZN, BNTX, MRNA, NVAX, PFE, CASBF, GSK, INO, SHTDY
CNBC - 7 months ago

The World Health Organization this week said 21 candidate vaccines are in clinical trials at the moment, meaning they are being tested on human volunteers.

Other stocks mentioned: AZN, MRNA
Business Wire - 8 months ago

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced an update to its previous...

Business Wire - 8 months ago

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial re...

The Motley Fool - 8 months ago

Not as quickly as anyone would like, but possibly sooner than some expect.

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, NVAX, PFE
Business Wire - 8 months ago

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced the China National Medica...

Benzinga - 8 months ago

Chinese biopharma Sinovac Biotech, which is one of 10 companies doing human testing of a vaccine candidate for SARS-CoV-2, the virus that causes COVID-19, announced positive preliminary data M...

The Motley Fool - 9 months ago

Size may matter in the long run.

Other stocks mentioned: BNTX, EBS, GSK, INO, JNJ, MRNA, NVAX, PFE, SNY

About SVA

Sinovac Biotech, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a ... [Read more...]

Industry
Biotechnology
Founded
1999
CEO
Wei Dong Yin
Employees
910
Stock Exchange
NASDAQ
Ticker Symbol
SVA
Full Company Profile

Financial Performance

In 2019, SVA's revenue was $246.05 million, an increase of 7.14% compared to the previous year's $229.65 million. Earnings were $44.93 million, an increase of 106.27%.

Financial Statements